moatshark My

All holdings

Biogen

BIIB

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$589k
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q2 ’26 end
$216.06
+17.9% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-16.4%Q3 ’24
-21.1%Q4 ’24
-10.5%Q1 ’25
-8.2%Q2 ’25
+11.5%Q3 ’25
+25.6%Q4 ’25
+4.2%Q1 ’26
+17.9%Q2 ’26
Q3 ’24: -16.4%; Q4 ’24: -21.1%; Q1 ’25: -10.5%; Q2 ’25: -8.2%; Q3 ’25: +11.5%; Q4 ’25: +25.6%; Q1 ’26: +4.2%; Q2 ’26: +17.9%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Biogen.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Biogen
Horizon Kinetics0.0%$589k$589kTrimmed -4.6%30 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Biogen
Bought or soldFiling
4 Aug 2026Minor LloydDirector▼ Sold593$200.96$119kForm 4
3 Aug 2026Minor LloydDirector▼ Sold593$203.34$121kForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
148m at 27 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$6.9bn2013
$11bn2015
$12bn2017
$14bn2019
$11bn2021
$9.8bn2023
$9.9bn2025
2013: $6.9bn; 2014: $9.7bn; 2015: $11bn; 2016: $11bn; 2017: $12bn; 2018: $13bn; 2019: $14bn; 2020: $13bn; 2021: $11bn; 2022: $10bn; 2023: $9.8bn; 2024: $9.7bn; 2025: $9.9bn
Biogen revenue and net income by year
YearRevenueNet income
2025$9.9bn$1.3bn
2024$9.7bn$1.6bn
2023$9.8bn$1.2bn
2022$10bn$3.0bn
2021$11bn$1.6bn
2020$13bn$4.0bn
2019$14bn$5.9bn
2018$13bn$4.4bn
2017$12bn$2.5bn
2016$11bn$3.7bn
2015$11bn$3.5bn
2014$9.7bn$2.9bn
2013$6.9bn$1.9bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.